PureTech Health plc American Depositary Shares - PRTC STOCK NEWS

PureTech Health plc announced positive results from a Phase 1 trial of LYT-100, demonstrating good tolerability and a favorable pharmacokinetic profile. The maximum tolerated dose was not reached, indicating further dose escalation studies are planned. The ongoing Phase 2 trial for Long COVID respiratory complications is on track for completion by year-end, with results expected in H1 2022. Future Phase 1 studies aim to clarify dosing and tolerability across various indications. These advancements underscore LYT-100's potential in treating inflammatory and fibrotic conditions.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) will participate in fireside chats at two key investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, and Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021.

Presenters include senior management members like George Farmer, Ph.D., and Daphne Zohar. Webcasts will be accessible via their investor relations page, reflecting their commitment to transparency and investor engagement.

PureTech Health is advancing its clinical trial for LYT-200, targeting challenging solid tumors like pancreatic cancer. The Phase 1/2 trial continues without reaching maximum tolerated dose, with initial results expected in H1 2022. The trial assesses LYT-200's safety, tolerability, and anti-tumor activity, both solo and with therapies like BeiGene's tislelizumab. Recently, LYT-200 received orphan drug designation from the FDA for pancreatic cancer, offering potential tax incentives and a chance for seven years of market exclusivity upon approval.

PureTech Health plc announced that the FDA granted orphan drug designation for its cancer treatment candidate, LYT-200, targeting pancreatic cancer. LYT-200, a human IgG4 monoclonal antibody, addresses poor survival rates in challenging solid tumors. Currently in a Phase 1/2 clinical trial, it has not yet reached the maximum tolerated dose. The designation allows for potential tax credits and seven years of market exclusivity upon approval. Topline results from the trial are expected in H1 2022.

Zai Lab has secured exclusive rights to develop and commercialize KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The agreement entails an upfront payment of $35 million to Karuna Therapeutics and potential milestone payments up to $152 million. Zai Lab will undertake the development and commercialization efforts, with tiered royalties on net sales. KarXT targets psychiatric conditions, showing promising results in late-stage trials for schizophrenia and Alzheimer's-related psychosis.

PureTech Health reported as of September 30, 2021, PureTech Level Cash and Cash Equivalents of $387.3 million and Consolidated Cash of $441.0 million. The company has raised $1.6 billion since July 2018, with 96% from third-party investors. Executives will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2021, at 7:20 AM EST. A webcast will be available online.

PureTech Health announces a groundbreaking paper published in Nature’s Scientific Reports detailing the development of the first superabsorbent hydrogel technology from naturally derived materials.

This innovation is aimed at addressing obesity and gut-related conditions by mimicking the properties of raw vegetables. The research shows that these hydrogels protect gut tissue from toxins in ex-vivo models. Their product, Plenity, is FDA-cleared and assists in weight management, with future product candidates poised to target various indications.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced the appointment of Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary for its Founded Entity, Vedanta Biosciences. Dr. Levi brings over 25 years of legal experience within the life sciences sector, having previously served at Cell Signaling Technology and Biogen. Her expertise in intellectual property, corporate governance, and complex transactions is expected to support Vedanta's goal of developing new oral therapies based on bacterial consortia.

Vedanta Biosciences has appointed Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary. With over 25 years of legal experience in the life sciences sector, including roles at Biogen and Cell Signaling Technology, Dr. Levi is expected to enhance Vedanta's legal framework as it develops oral therapies targeting the microbiome. Her appointment aligns with Vedanta's vision to innovate in drug delivery systems. The company holds over 40 patents and is recognized for its extensive library of beneficial bacteria.